Beneufit's pdFIT™ Parkinson's Disease Pilot Study Data
SAN FRANCISCO, Calif. (PRWEB) November 06, 2014
Beneufit, Inc. is pleased to announce the results of a 12 week Pilot Study in which Parkinson’s disease subjects using pdFIT™ improved their motor function and fitness capacity. For the first time, a company has delivered personalized exercise protocols to Parkinson’s disease subjects and quantified positive results longitudinally through proprietary measures of fitness and manual dexterity. During the study period subjects increased their fitness capacity as measured by Beneufit’s fitFactor™ score by 38% and manual dexterity as measured by their circleTap™ score by 25%.
Key Points:
- 12-week study period
- 25% increase in circleTap™ test scores (measure of manual dexterity)
- 38% increase in fitFactor™ scores (measure of compliance to prescribed workout protocols)
- Average patient age: 70 years old
- Average workouts per week: 2.24
- Average circleTap™ tests per week: 1.43
Jeff Broderick, CEO of Beneufit, said, “The results of the study are important for Parkinson’s disease patients who are fighting to remain independent and delay disease progression. Increased manual dexterity is a key factor for Parkinson’s patients and can make a huge difference in routine tasks like brushing teeth and shampooing hair. In addition to the measurable increase in manual dexterity and fitness levels, Beneufit subjects experienced material improvements in quality of life factors including increased sleep time, strength and control over symptoms.”
About pdFIT™
pdFIT™ is a disease management solution for Parkinson’s disease patients. The goal of the program is to reduce symptoms, delay disease progression and improve quality of life by augmenting current treatment regimens with exercise. This outcome-based approach to chronic disease management is unique in that it utilizes personalized, disease-specific exercise protocols, analytics, wearable technologies and mobile devices to improve patient outcomes.
About Parkinson’s Disease
Parkinson’s disease is a neurodegenerative disease affecting 5 million people worldwide. The disease is caused by death of dopamine-generating neurons in the brain’s substantia nigra. Symptoms include tremor, rigidity, slowness and postural instability. Medication only offers symptomatic relief for a period of time. No medication halts or slows down the progression of the disease. Recent studies suggest exercise increases dopamine D2 receptor expression.
Access Beneufit Parkinson’s Disease Pilot Study
http://beneufit.com/sites/default/files/BeneufitParkinsonsDiseasePilotStudy2014.pdf
These positive results set the stage for a large formal study with biopharmaceutical company and healthcare system partners.
About Beneufit, Inc.
Beneufit offers a chronic disease management platform designed for patients. Our goal is to improve patient conditions, improve customer experiences and reduce healthcare costs by augmenting current treatment regimens with exercise. By helping patients, Beneufit supports the efforts of biopharmaceutical companies and healthcare providers by providing outcome-based services to their customers.
Contact
Beneufit, Inc.
Jeff Broderick, CEO
930 Montgomery Street, Suite 501,
San Francisco, CA 94133
415-500-2770
info(at)beneufit(dot)com
http://www.beneufit.com